Roger Longman

Real Endpoints believes that the single biggest challenge to the long-term health of medical innovation is getting it paid for. In a world where healthcare decision-making is increasingly concentrated in a consolidating set of ever-more powerful industrial customers, RE focuses entirely on delivering solutions that enhance appropriate access to innovation. To do this, we leverage insights from our close working relationships with payers and biopharma; objective, data-driven proprietary tools; and – above all – the creativity and deep experience of our people. In particular, RE focuses on three main activities: • Helping to define, through objective clinical and economic assessment and practical evidence strategies, a product’s value for patients and payers; • Translating that value into coverage with effective pricing strategies and innovative, contracting approaches, including risk sharing and outcomes-focused arrangements; • And finally, strategies for supporting patients and providers in order to go beyond mere coverage and win actual access to new diagnostics and medicines. To date, RE has worked with dozens of biopharmas, diagnostics players, and payers to make it possible for patients to benefit, affordably, from the extraordinary innovations of life science companies…and simultaneously keep the ultimate fuel of this industry – meaningful reimbursement – flowing.